Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Apple Turns 50: From Garage Startup to AI Crossroads 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
(4) - EconoTimes)
SOUTH SAN FRANCISCO, Calif., July 27, 2017 -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on July 25, 2017, the Compensation Committee of the Board of Directors approved, effective as of July 31, 2017, the grant of inducement stock options to purchase an aggregate of 342,000 shares of common stock to 53 new employees.
Each stock option shall have an exercise price per share equal to the closing price per share of the Company’s Common Stock on July 31, 2017, and will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares vest ratably over the subsequent 36 months, subject to each new employee's continued service with the Company. Each stock option has a ten year term and is subject to the terms and conditions of the Company's Inducement Plan and the stock option agreement pursuant to which the option was granted.
The stock options were granted as inducements material to the new employees entering into employment with Portola in accordance with NASDAQ Listing Rule 5635(c)(4).
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Mardi Dier, CFO Portola Pharmaceuticals [email protected] Media Contact: Julie Normart Pure Communications [email protected] 415.946.1087
